Hims & Hers has withdrawn its $49 compounded semaglutide pill after pressure from top U.S. health officials at the FDA and ...

HealthDay News — Hims & Hers says it will stop selling a low-cost copy of a new weight-loss pill made by Novo Nordisk, after federal officials raised concerns that the product may violate drug laws.

Key Takeaways On Feb. 6, 2026, FDA announced that it would take action to restrict access to GLP-1 ingredients for non-FDA ...

The agency flagged several violations at a compounding pharmacy owned by Hims & Hers, including “infestation by rodents, ...

FDA inspectors found a live spider and dead cricket in a facility that was compounding weight loss drugs for Hims & Hers.

FDA enforcement will focus on restricting GLP-1 APIs in mass-marketed, nonapproved compounded products to address unverifiable quality, safety, and efficacy under the FD&C Act. Appropriate compounding ...

Novo is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe patents, and is ...

Novo Nordisk threatens legal action against Hims & Hers for "duping" public with cheap compounds of its popular weight-loss ...

As Super Bowl Sunday approaches, the battle off the field for advertisers to win over 120 million-plus viewers will be just ...

Wistar scientists have combined a promising cancer therapy with a molecule that targets tumors to treat cancer more ...

In a direct challenge to the booming obesity-drug business, telehealth company Hims & Hers has rolled out what it says is the ...

Hims said it would sell a copy of the newly launched weight loss pill for $49, far less than the $149 Novo sells the branded pill for.